Potential treatment for TB solves puzzle

Scientists have uncovered a new target for the potential treatment of TB, finally resolving a long-running debate about how the bacterial cell wall is built. The research, published in the July issue of Microbiology reveals several molecules that could be developed into drugs to treat tuberculosis.

Multi drug-resistant strains of Mycobacterium tuberculosis, the bacterium that causes TB, sparked concern but the recent emergence of extensively drug-resistant strains (XDR-TB) means the search for new treatments is imperative.

Unlike human cells, bacteria have cell walls. Molecules called mycolic acids form a vital part of these walls. To produce them, bacteria carry out several processes but until recently, scientists were unsure of the genes that control each step. One vital step is dehydration - the removal of a water molecule to lengthen the acid chain. Researchers from the University of Birmingham have shown that the gene Rv0636 controls this step, which provides new avenues for the development of treatments for TB.

"FAS-II is a group of enzymes that work together to carry out dehydration," said Professor Gurdyal Besra from the University of Birmingham. "We know that the molecules NAS-21 and NAS-91 can stop these enzymes from building cell walls, so we looked at their effect on Mycobacteria. We also wanted to find out if one of the enzymes is coded for by the gene Rv0636."

Professor Besra and his colleagues made modifications to NAS-21 and NAS-91, making several analogues based on the original molecules. They then tested these analogues to see if they stopped the enzymes from working. "Both series of compounds demonstrated activity against the FAS-II enzymes alone," said Professor Besra. "When we tested them against live bacterial cells we noticed that some of the analogues stopped the cells from building mycolic acids, which effectively killed them.

"We also tested them on bacteria that were overexpressing Rv0636, which meant they were producing extra enzymes. These cells were resistant to NAS-21 and NAS-91, suggesting that the gene Rv0636 does code for an enzyme in the FAS-II complex," said Professor Besra. "So we have solved the mystery.

The researchers have also identified a new class of compounds that could be developed into successful treatments for tuberculosis that are urgently required in the future. "The emergence of drug-resistant strains of Mycobacterium tuberculosis has highlighted the need for new TB drugs. We hope our discovery will lead to a new rationale for the design of treatments," said Professor Besra.

Source: Society for General Microbiology

Related stories:

Clue to genetic cause of fatal birth defect
A novel enzyme may play a major role in anencephaly, offering hope for a genetic test or even therapy for the rare fatal birth defect in which the brain fails to develop, according to a study from researchers at the University of Illinois at Chicago College of Medicine.
Keeping herpes infection in check: researchers describe immune system strategies
Herpes simplex virus type I can cause bouts of cold sores, blindness and potentially lethal encephalitis when it reawakens from a quiescent state in the nerve cells it infects.
Scientists simulate gut reaction to arsenic exposure
A simulated gastrointestinal system is helping scientists test contaminated soil for its potential to harm humans. The method is likely to save time and money for people hoping to repurpose land with an industrial past.
Landmark discovery of 'engine' that drives cell movement
This research by Thomas Leung, Ph.D., and his team in the GSK-IMCB Group at the Institute of Molecular and Cell Biology (IMCB), under Singapore's Agency for Science, Technology and Research, is fundamental to the understanding of how assembles its internal machinery required for cell movement.
Food for thought -- regulating energy supply to the brain during fasting
If the current financial climate has taught us anything, it's that a system where over-borrowing goes unchecked eventually ends in disaster. It turns out this rule applies as much to our bodies as it does to economics. Instead of cash, our body deals in energy borrowed from muscle and given to the brain.
Researchers propose minocycline as a promising drug for patients with Fragile X syndrome
A UC Riverside-led team of biomedical scientists has found that a readily available drug called minocycline, used widely to treat acne and skin infections, can be used to treat Fragile X syndrome, the most common inherited cause of mental impairment and the most common cause of autism.
'Hub' of fear memory formation identified in brain cells
A protein required for the earliest steps in embryonic development also plays a key role in solidifying fear memories in the brains of adult animals, scientists have revealed. An apparent "hub" for changes in the connections between brain cells, beta-catenin could be a potential target for drugs to enhance or interfere with memory formation.
Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology.

News discussion:

General Science news